MNTA - Momenta Pharmaceuticals, Inc.

NasdaqGS - NasdaqGS Delayed Price. Currency in USD

Momenta Pharmaceuticals, Inc.

675 West Kendall Street
Cambridge, MA 02142
United States
617-491-9700
http://www.momentapharma.com

SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic
Full Time Employees279

Key Executives

NameTitlePayExercisedYear Born
Mr. Craig A. WheelerPres, CEO & Exec. Director1.27MN/A1960
Dr. Ganesh Venkataraman Kaundinya Ph.D.Co-Founder, COO, Chief Scientific Officer & Sr. VP648.27kN/A1967
Mr. Scott M. StorerSr. VP, CFO & Principal Accounting Officer40.53kN/AN/A
Mr. Bruce A. Leicher J.D.Sr. VP, Gen. Counsel and Corp. Sec.620.78kN/A1956
Dr. Young T. Kwon Ph.D.Sr. VP of Corp. Devel. & StrategyN/AN/AN/A
Amounts are as of December 31, 2016 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Momenta Pharmaceuticals, Inc., a biotechnology company, focuses on developing generic versions of complex drugs, biosimilars, and novel therapeutics for autoimmune diseases in the United States. The company's complex generics programs include Enoxaparin sodium injection, a generic version of Lovenox that is indicated for the prevention and treatment of deep vein thrombosis, as well as supports the treatment of acute coronary syndromes; GLATOPA, a generic version of once-daily COPAXONE for the treatment of patients with relapsing-remitting multiple sclerosis; and GLATOPA, a generic product candidate for three-times-weekly COPAXONE. Its biosimilars programs comprise M923, a biosimilar of HUMIRA for the treatment of patients with rheumatoid arthritis, crohn's disease, ulcerative colitis, and psoriasis; and M834, a biosimilar of ORENCIA for the treatment of rheumatoid arthritis and juvenile idiopathic arthritis, as well as other biosimilar candidates. The company's novel therapeutics programs include M254, a hyper-sialylated version of intravenous immunoglobulin to treat various inflammatory diseases, including idiopathic thrombocytopenic purpura, chronic inflammatory demyelinating polyneuropathy, and multifocal motor neuropathy; M281, a fully-human anti-neonatal Fc receptor (FcRn), aglycosylated immunoglobulin G (IgG1), and monoclonal antibody to reduce circulating IgG antibodies by blocking endogenous IgG recycling via FcRn; and M230, a recombinant trivalent human IgG1 Fc multimer to block tissue damage mediated by immune complexes. It has collaboration and license agreements with Sandoz AG, Mylan Ireland Limited, and CSL Behring Recombinant Facility AG. The company was formerly known as Mimeon, Inc. and changed its name to Momenta Pharmaceuticals, Inc. in September 2002. Momenta Pharmaceuticals, Inc. was founded in 2001 and is headquartered in Cambridge, Massachusetts.

Corporate Governance

Momenta Pharmaceuticals, Inc.’s ISS Governance QualityScore as of April 1, 2018 is 3. The pillar scores are Audit: 1; Board: 2; Shareholder Rights: 6; Compensation: 4.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.